Resources Repository
-
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Policy/Regulation | Chronic Disease/Risk | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Health/Medicine | Global -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Chronic Disease/Risk | Cost-Effectiveness Analysis | Health/Medicine | North America -
Resource PackPublication, Teaching Resource 2024Resource Pack: Extended Cost-Effectiveness Analysis
Health policies are intended to increase the uptake of effective and efficient interventions and result …
Health policies are intended to increase the uptake of effective and efficient interventions and result in health gains (e.g., premature mortality and morbidity averted). Health policies can also provide non-health benefits in addition to the sole well-being of populations and beyond the health sector. For instance, social and health insurance programs can prevent illness-related impoverishment and provide financial risk protection. Health policies can also improve the distribution of health in the population and promote health…
Policy/Regulation | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Culture/Society | Economics/Finance | Health/Medicine | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ArticlePublication 2024Hepatitis C Elimination in Rwanda: Progress, Feasibility, Economic Evaluation
This study evaluates the impact of Rwanda's national program launched in 2018 to eliminate hepatitis …
This study evaluates the impact of Rwanda's national program launched in 2018 to eliminate hepatitis C virus (HCV) and identifies strategies to achieve World Health Organization (WHO) elimination goals by 2030. Employing a microsimulation model spanning 2015 to 2050, the analysis assesses HCV epidemic trends, prevalence, mortality, and total care costs under various scenarios. Results show that between 2018 and 2022, over 7 million people were screened and 60,000 treated, projecting Rwanda's potential achievement of…
Chronic Disease/Risk | Microsimulation | Infectious Diseases | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2024Disparities in TB Incidence by Race & Ethnicity Among the U.S.-Born Population in the U.S., 2011 to 2021
This study aims to assess trends in racial/ethnic disparities in tuberculosis (TB) incidence among U.S.-born …
This study aims to assess trends in racial/ethnic disparities in tuberculosis (TB) incidence among U.S.-born individuals from 2011 to 2021. Using national TB registry data, time-series analysis was conducted, stratifying by race/ethnicity and adjusting for age, year, and state of residence. Results indicate persistent disparities, with incidence rate ratios as high as 14.2 for American Indian or Alaska Native (AI/AN) females compared to non-Hispanic White individuals. Relative disparities were more pronounced for females, younger individuals,…
Chronic Disease/Risk | Infectious Diseases | Health/Medicine | North America -
ArticlePublication 2024Hypertension Care Cascades and Reducing Inequities in Cardiovascular Disease in LMIC
This study investigates the distributional implications of enhancing hypertension control in low- and middle-income countries …
This study investigates the distributional implications of enhancing hypertension control in low- and middle-income countries (LMICs) across wealth quintiles. Using individual-level data from nationally representative surveys in 44 LMICs, the researchers simulated improvements in the hypertension care cascade and assessed the distributional benefits. They raised diagnosis and treatment levels for all wealth quintiles to match the best-performing country quintile and estimated the resulting change in 10-year cardiovascular disease (CVD) risk. Results indicate greater health benefits…
Chronic Disease/Risk | Cost-Effectiveness Analysis | Health/Medicine -
Working PaperPublication 2024Economic Evaluation Primer
Economic evaluation is a powerful tool, encouraging the systematic collection and assessment of the evidence …
Economic evaluation is a powerful tool, encouraging the systematic collection and assessment of the evidence needed to support sound policy decisions. In low- and middle-income countries, where resources are especially scarce and needs are very great, such decisions are exceptionally difficult. In these settings, economic evaluation can be particularly useful in determining how to best improve health and welfare. Typically, cost-effectiveness analysis (CEA) is used to prioritize interventions within the health care sector. This approach…
Policy/Regulation | Priority Setting/Ethics | Costing Methods | Health Outcomes | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Global -
ArticlePublication 2023Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control …
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the US. A cost-effectiveness analysis was conducted using a Markov model based on the pharmacist-prescribing intervention used in The Alberta Clinical Trial in Optimizing Hypertension (or RxACTION). Outcomes included cardiovascular (CV) events, end-stage kidney disease events, life years, quality-adjusted life years (QALYs), lifetime costs, and lifetime incremental cost-effectiveness ratio (ICER). Costs were based on reimbursement rates, published literature, national…
Chronic Disease/Risk | Mathematical Models | State-Transition | Cost-Effectiveness Analysis | Clinical Care | Health/Medicine | North America -
ArticlePublication 2023Cost-Effectiveness of Intensive vs. Standard Blood Pressure Control Among Older Patients
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older …
This economic analysis explored the cost-effectiveness of intensive vs standard blood pressure control in older hypertensive patients between 60 and 80 years in China, the US, and the UK. Treatment outcome data from the Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP trial) and different cardiovascular risk assessment models for a hypothetical cohort of STEP-eligible patients were used. Costs and utilities were obtained from published sources. A Markov model was used to…
Chronic Disease/Risk | Mathematical Models | Cost-Effectiveness Analysis | Clinical Care | North America